Skip to main content
Evidence Snapshot

Nuclear receptor subfamily 1 group I member 2

CHEMBL3401 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:29Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3401
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Nuclear receptor subfamily 1 group I member 2 as ChEMBL target CHEMBL3401, mapped to UniProt O75469. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Nuclear receptor subfamily 1 group I member 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3401
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O75469
Nuclear receptor subfamily 1 group I member 2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Nuclear receptor subfamily 1 group I member 2 matters

As of 2026-09-14

Nuclear receptor subfamily 1 group I member 2 is reviewed as Nuclear receptor subfamily 1 group I member 2 (UniProt O75469); the current evidence base includes 43 approved drugs, 3575 compounds, and 678 assays, with lead potency reaching pChEMBL 9.2.

Protein context
Nuclear receptor subfamily 1 group I member 2

Nuclear receptor subfamily 1 group I member 2 Sequence length is 434 aa.

Review this target as Nuclear receptor subfamily 1 group I member 2, mapped to UniProt O75469. Sequence length is 434 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt O75469 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 43 approved drugs, 3575 compounds, and 678 assays for this target. The dominant activity type is EC50. CHEMBL463678 is the current potency anchor at pChEMBL 9.2.

Use CHEMBL463678 as the tractability anchor when discussing potency (pChEMBL 9.2).

Activity source · ChEMBL 36 via Core Engine
43 approved pChEMBL 9.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Nuclear receptor subfamily 1 group I member 2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt O75469, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3575
Total Compounds
678
Total Assays
43
Approved Drugs
IC50: 557.0, KI: 5.0, EC50: 1358.0, KD: 1.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL463678
 9.2 EC50 —
No preferred name
CHEMBL5284539
 9.0 IC50 —
No preferred name
CHEMBL464497
 8.8 EC50 —
No preferred name
CHEMBL5286515
 8.8 IC50 —
No preferred name
CHEMBL8739
 8.7 EC50 —

Approved Drugs

Structure Compound First Approval
DROXIDOPA
CHEMBL2103827
 2014
DABRAFENIB
CHEMBL2028663
 2013
SIROLIMUS
CHEMBL413
 1999
ZAFIRLUKAST
CHEMBL603
 1996
RIMEXOLONE
CHEMBL1200617
 1994
NIMODIPINE
CHEMBL1428
 1988
RIFAMPIN
CHEMBL374478
 1971
BITHIONOL
CHEMBL290106
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:29Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3401